CancerFax
COST GUIDE Β· DETAILED BREAKDOWN

CAR-T PROGRAMME COST
IN INDIA: FULL BREAKDOWN

India's NexCAR19 CAR-T episode costs $35,000–55,000 all-in β€” the lowest cost for any commercially approved CAR-T programme globally. Here is a line-by-line breakdown.

Send Your ReportsContact Us

analyticsAt a Glance

  • check_circleNexCAR19 drug and manufacturing fee: Rs 25–35 lakh (~$30,000–42,000)
  • check_circleTotal all-in episode (NexCAR19): approximately $35,000–55,000 USD
  • check_circleKymriah all-in in India: $145,000–195,000 β€” 3–4Γ— more expensive
  • check_circleInternational patient travel and accommodation adds approximately $3,000–8,000
Reviewed by: CancerFax Medical Team, Oncology & Haematology SpecialistsLast reviewed: June 9, 2026

NexCAR19 Cost Components: Line-by-Line

The NexCAR19 episode comprises several discrete cost components. Most are billed separately by the hospital. International patients should budget for all items below.

Cost ComponentINR (Approximate)USD (Approximate)Notes
NexCAR19 drug / manufacturing feeRs 25–35 lakh$30,000–42,000Paid to ImmunoACT via the treating hospital
Pre-treatment workupRs 80,000–1,50,000$1,000–1,800Bone marrow biopsy, flow cytometry, organ function, cardiac echo, infectious disease screen
Lymphodepletion chemotherapy (flu/cy)Rs 40,000–80,000$500–1,000Fludarabine + cyclophosphamide administered 3 days before infusion
Inpatient stay (2–4 weeks post-infusion)Rs 2–6 lakh$2,400–7,200ICU/HDU if CRS or ICANS; general ward if uncomplicated
Tocilizumab biosimilar (if CRS grade 2+)Rs 15,000–35,000 / dose$180–420 / dose1–2 doses needed in approximately 35–40% of cases
IVIG (first infusion)Rs 5,000–15,000$60–180If IgG < 500 mg/dL at discharge β€” often not needed at discharge
Prophylaxis drugs (cotrimoxazole, antiviral, antifungal)Rs 2,000–5,000 / month$25–60 / monthGenerics widely available in India
Physician fees (haematologist, ICU, neurology consult)Rs 50,000–1,50,000$600–1,800Varies by centre and complexity

Total Episode Cost Summary

  • $35–55KNexCAR19 All-In Episode (India)Total estimated cost including drug, hospitalisation, workup, and supportive medications β€” no hidden exclusions.
  • $145–195KKymriah All-In Episode (India)Tisagenlecleucel (Novartis Kymriah) at select Indian centres β€” 3–4Γ— more expensive than NexCAR19.
  • $475K+Kymriah All-In Cost in USAListed price in the United States plus hospital fees β€” effectively inaccessible without insurance.
  • $3–8KTravel and Accommodation (International Patients)Approximate cost for patient + 1 companion: return flights, 6–8 weeks accommodation near TMC/Apollo.

CAR-T Cost by Country: India vs Global

All-in episode cost comparison for CD19 CAR-T therapy across major countries β€” illustrating India's cost leadership.

CD19 CAR-T All-In Episode Cost (USD)

  • India (NexCAR19)$35–55K
  • India (Kymriah)$145–195K
  • China$80–150K
  • EU / UK$350K+
  • USA (Kymriah / axi-cel)$475K+

NexCAR19 vs Kymriah in India: Which to Choose?

Both NexCAR19 and Kymriah (tisagenlecleucel) are commercially available in India. The choice between them has clinical and financial dimensions.

  • NexCAR19 β€” The Cost Case

    NexCAR19 at Rs 25–35 lakh is the first choice for most international patients on cost grounds. Published efficacy data from the pivotal trial show response rates competitive with global benchmarks for B-ALL and DLBCL.

  • Kymriah β€” When to Consider

    Kymriah may be preferred when the patient specifically has paediatric ALL (aged under 25, where Kymriah's ELIANA trial data are most established), or when the treating physician has strong institutional experience with tisagenlecleucel specifically.

  • Insurance Coverage

    Some patients from the Gulf, Europe, or Southeast Asia carry private insurance that may partially cover CAR-T. Kymriah β€” as a globally recognised branded product β€” may be more likely to attract insurance reimbursement than NexCAR19. Check your policy before committing.

  • Centre Selection

    NexCAR19 is available at TMC Mumbai (highest volume), Apollo, Manipal, and a growing number of Indian centres. Kymriah is available at select Apollo and Manipal centres. TMC is the primary NexCAR19 centre and offers the most mature programme.

Budgeting for International Patients

International patients need to budget beyond the hospital bill. The following estimates are for a patient plus one companion from South Asia or East Africa.

  • Return Flights

    Dhaka–Mumbai return (patient + companion): approximately $400–700. Nairobi–Mumbai return (patient + companion): approximately $800–1,200. Budget airlines and advance booking reduce costs further.

  • Accommodation in Mumbai

    Parel area (near TMC): Rs 1,500–4,000/night ($18–48) for a decent guesthouse or service apartment. For 6–8 weeks: approximately Rs 65,000–1,80,000 ($800–2,200).

  • Food and Local Transport

    Daily food and local transport in Mumbai for two people: approximately Rs 1,000–2,000/day ($12–24). Over 6–8 weeks: approximately $500–1,000.

  • Visa Fees

    Indian medical e-visa: approximately $25–50 per person. Companion medical attendant visa: same. Budget Rs 4,000–8,000 total for visa fees.

More from the CAR-T India Resource Library

Explore related guides on CAR-T access, NexCAR19 vs Kymriah, and how CancerFax helps with the process.

Frequently Asked Questions β€” CAR-T Cost in India

  • Why is NexCAR19 cheaper than Kymriah in India?

    NexCAR19 is manufactured in India by ImmunoACT, a joint venture of IIT Bombay and Tata Memorial Centre. Local manufacturing eliminates import costs, royalties, and global pricing premiums. Kymriah is manufactured by Novartis in Switzerland and imported β€” carrying full global price structure. India's own manufacturing capability is the specific reason NexCAR19 can be priced 5–10Γ— below Kymriah.

  • Is the Rs 25–35 lakh figure the total cost or just the drug fee?

    Rs 25–35 lakh is the drug and manufacturing fee charged by ImmunoACT. The total episode β€” including hospitalisation, workup, lymphodepletion chemotherapy, supportive medications, and physician fees β€” adds Rs 4–12 lakh on top. The all-in total is approximately Rs 30–50 lakh ($36,000–60,000 USD). CancerFax provides a detailed estimate based on your specific case before travel.

  • Are there hidden costs I should be aware of?

    The main variable costs that can increase the total are: (1) CRS requiring multiple tocilizumab doses (each Rs 15,000–35,000); (2) ICANS requiring prolonged ICU stay; (3) infection complications extending hospitalisation; and (4) the need for IVIG at discharge. CancerFax builds a worst-case budget estimate for patients that accounts for these scenarios β€” not just the best-case minimum.

  • Can I pay in installments or use a medical loan?

    Some Indian hospitals partner with medical finance providers that offer EMI options for Indian residents. For international patients, most hospitals require full pre-payment of the NexCAR19 manufacturing fee before leukapheresis. Other components can sometimes be settled on a rolling basis. CancerFax can advise on the current payment terms at the specific centre you are considering.

How CancerFax Helps

CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.

description
Medical Record Review

We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.

verified_user
Eligibility Coordination

We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.

hub
Hospital Communication

We support appointment coordination, document submission, translation, and direct communication with international departments.

flight
Travel & Admission Support

For international patients, we help with practical coordination β€” travel planning, hospital admission guidance, and local support.

explore
Treatment & Trial Navigation

If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.

support_agent
End-to-end Coordination

From inquiry through to follow-up, our coordinators provide a single point of contact for the family.

Send Medical ReportsSpeak With CancerFax

CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.

Want a Cost Estimate for Your Specific Case?

CancerFax provides a personalised cost estimate based on your diagnosis, hospital preference, and country of origin before you commit to travel.

Send Your ReportsContact Us

Cost estimates are indicative and subject to clinical factors. Final costs are determined by the treating centre.